A new design of trial for hypnotics comparison: A double-blind cross-over trial with patient's preference assessment and continuation of the preferred treatment
1. 1. This study compared two hypnotics administrated at comparable therapeutic dosages: triazolam (0.25 mg) and loprazolam (1 mg), were administered using an original scheme (cross-over on the first 2 nights, and continuation of the preferred treatment or new randomization). 2. 2. Sixty-seven outpa...
Gespeichert in:
| Veröffentlicht in: | Progress in neuro-psychopharmacology & biological psychiatry 1996-04, Vol.20 (3), p.373-385 |
|---|---|
| Hauptverfasser: | , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 385 |
|---|---|
| container_issue | 3 |
| container_start_page | 373 |
| container_title | Progress in neuro-psychopharmacology & biological psychiatry |
| container_volume | 20 |
| creator | Bourin, Michel Malinge, Myriam |
| description | 1.
1. This study compared two hypnotics administrated at comparable therapeutic dosages: triazolam (0.25 mg) and loprazolam (1 mg), were administered using an original scheme (cross-over on the first 2 nights, and continuation of the preferred treatment or new randomization).
2.
2. Sixty-seven outpatients complaining of common insomnia participated in this study conducted by general practitioners.
3.
3. Both drugs provided improvement in sleep quality (decreased sleep latency, increased total duration of sleep, decreased number of night awakenings), and are equally well tolerated.
4.
4. For the first 2 nights, triazolam was evaluated to be more efficient than loprazolam (p < 0.001) and patients felt more rested the following day (p < 0.01) with the former drug. Moreover, triazolam is more frequently preferred than loprazolam by 47.7% and 29.2%, respectively, (p = 0.09).
5.
5. No interaction was found between treatment and order of administration or specific effects and order of administration. |
| doi_str_mv | 10.1016/0278-5846(96)00003-6 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_78275509</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>0278584696000036</els_id><sourcerecordid>78275509</sourcerecordid><originalsourceid>FETCH-LOGICAL-c386t-84952c58b0119cc32d77f6d8eeba74ae869608812593da19a57c14021d72363f3</originalsourceid><addsrcrecordid>eNp9kc-O1SAUxonRjNfRN9CEhfHPogqlBToLk5uJzkwyiRtdEwqnXkwLFehM5m18VKm3ucthQzj8vsPh-xB6TcknSij_TGohq1Y2_EPHP5KyWMWfoB2VpdzUlD9FuxPyHL1I6XdhKCPsDJ1JIWjbtTv0d4893GMLyf3yOAw4R6dHPISIDw-zD9mZhE2YZh1dCv4C77ENSz9C1Y_OW2xiSKkKdxA35b3LBzzr7MDn9wnPEQaI4A1gnRKkNJU61qsy-Oz8UshwfPgAGx3Blmag88q-RM8GPSZ4te3n6Oe3rz8ur6vb71c3l_vbyjDJcyWbrq1NK3tCaWcMq60QA7cSoNei0SB5x4mUtG47ZjXtdCsMbUhNragZZwM7R--OfecY_iyQsppcMjCO2kNYkhKyFm1LugI2R_D_18vAao5u0vFBUaLWYNTqulpdV105rMEoXmRvtv5LP4E9ibYkyv3b7V4no8cham9cOmGMlFhZU7AvRwyKF3cOokrGrfZaF8FkZYN7fI5_h8GsKQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>78275509</pqid></control><display><type>article</type><title>A new design of trial for hypnotics comparison: A double-blind cross-over trial with patient's preference assessment and continuation of the preferred treatment</title><source>MEDLINE</source><source>Access via ScienceDirect (Elsevier)</source><creator>Bourin, Michel ; Malinge, Myriam</creator><creatorcontrib>Bourin, Michel ; Malinge, Myriam</creatorcontrib><description>1.
1. This study compared two hypnotics administrated at comparable therapeutic dosages: triazolam (0.25 mg) and loprazolam (1 mg), were administered using an original scheme (cross-over on the first 2 nights, and continuation of the preferred treatment or new randomization).
2.
2. Sixty-seven outpatients complaining of common insomnia participated in this study conducted by general practitioners.
3.
3. Both drugs provided improvement in sleep quality (decreased sleep latency, increased total duration of sleep, decreased number of night awakenings), and are equally well tolerated.
4.
4. For the first 2 nights, triazolam was evaluated to be more efficient than loprazolam (p < 0.001) and patients felt more rested the following day (p < 0.01) with the former drug. Moreover, triazolam is more frequently preferred than loprazolam by 47.7% and 29.2%, respectively, (p = 0.09).
5.
5. No interaction was found between treatment and order of administration or specific effects and order of administration.</description><identifier>ISSN: 0278-5846</identifier><identifier>EISSN: 1878-4216</identifier><identifier>DOI: 10.1016/0278-5846(96)00003-6</identifier><identifier>PMID: 8771595</identifier><identifier>CODEN: PNPPD7</identifier><language>eng</language><publisher>Amsterdam: Elsevier Inc</publisher><subject>Adult ; Anti-Anxiety Agents - therapeutic use ; Benzodiazepines ; Benzodiazepinones - therapeutic use ; Biological and medical sciences ; common insomnia ; cross-over trial ; Female ; Humans ; Hypnotics. Sedatives ; loprazolam ; Male ; Medical sciences ; Middle Aged ; Neuropharmacology ; patient's preference ; Pharmacology. Drug treatments ; Psychology. Psychoanalysis. Psychiatry ; Psychopharmacology ; Sleep Initiation and Maintenance Disorders - drug therapy ; triazolam ; Triazolam - therapeutic use</subject><ispartof>Progress in neuro-psychopharmacology & biological psychiatry, 1996-04, Vol.20 (3), p.373-385</ispartof><rights>1996</rights><rights>1996 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c386t-84952c58b0119cc32d77f6d8eeba74ae869608812593da19a57c14021d72363f3</citedby><cites>FETCH-LOGICAL-c386t-84952c58b0119cc32d77f6d8eeba74ae869608812593da19a57c14021d72363f3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/0278-5846(96)00003-6$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>315,781,785,3551,27928,27929,45999</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=3087834$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/8771595$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Bourin, Michel</creatorcontrib><creatorcontrib>Malinge, Myriam</creatorcontrib><title>A new design of trial for hypnotics comparison: A double-blind cross-over trial with patient's preference assessment and continuation of the preferred treatment</title><title>Progress in neuro-psychopharmacology & biological psychiatry</title><addtitle>Prog Neuropsychopharmacol Biol Psychiatry</addtitle><description>1.
1. This study compared two hypnotics administrated at comparable therapeutic dosages: triazolam (0.25 mg) and loprazolam (1 mg), were administered using an original scheme (cross-over on the first 2 nights, and continuation of the preferred treatment or new randomization).
2.
2. Sixty-seven outpatients complaining of common insomnia participated in this study conducted by general practitioners.
3.
3. Both drugs provided improvement in sleep quality (decreased sleep latency, increased total duration of sleep, decreased number of night awakenings), and are equally well tolerated.
4.
4. For the first 2 nights, triazolam was evaluated to be more efficient than loprazolam (p < 0.001) and patients felt more rested the following day (p < 0.01) with the former drug. Moreover, triazolam is more frequently preferred than loprazolam by 47.7% and 29.2%, respectively, (p = 0.09).
5.
5. No interaction was found between treatment and order of administration or specific effects and order of administration.</description><subject>Adult</subject><subject>Anti-Anxiety Agents - therapeutic use</subject><subject>Benzodiazepines</subject><subject>Benzodiazepinones - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>common insomnia</subject><subject>cross-over trial</subject><subject>Female</subject><subject>Humans</subject><subject>Hypnotics. Sedatives</subject><subject>loprazolam</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Neuropharmacology</subject><subject>patient's preference</subject><subject>Pharmacology. Drug treatments</subject><subject>Psychology. Psychoanalysis. Psychiatry</subject><subject>Psychopharmacology</subject><subject>Sleep Initiation and Maintenance Disorders - drug therapy</subject><subject>triazolam</subject><subject>Triazolam - therapeutic use</subject><issn>0278-5846</issn><issn>1878-4216</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1996</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kc-O1SAUxonRjNfRN9CEhfHPogqlBToLk5uJzkwyiRtdEwqnXkwLFehM5m18VKm3ucthQzj8vsPh-xB6TcknSij_TGohq1Y2_EPHP5KyWMWfoB2VpdzUlD9FuxPyHL1I6XdhKCPsDJ1JIWjbtTv0d4893GMLyf3yOAw4R6dHPISIDw-zD9mZhE2YZh1dCv4C77ENSz9C1Y_OW2xiSKkKdxA35b3LBzzr7MDn9wnPEQaI4A1gnRKkNJU61qsy-Oz8UshwfPgAGx3Blmag88q-RM8GPSZ4te3n6Oe3rz8ur6vb71c3l_vbyjDJcyWbrq1NK3tCaWcMq60QA7cSoNei0SB5x4mUtG47ZjXtdCsMbUhNragZZwM7R--OfecY_iyQsppcMjCO2kNYkhKyFm1LugI2R_D_18vAao5u0vFBUaLWYNTqulpdV105rMEoXmRvtv5LP4E9ibYkyv3b7V4no8cham9cOmGMlFhZU7AvRwyKF3cOokrGrfZaF8FkZYN7fI5_h8GsKQ</recordid><startdate>19960401</startdate><enddate>19960401</enddate><creator>Bourin, Michel</creator><creator>Malinge, Myriam</creator><general>Elsevier Inc</general><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>19960401</creationdate><title>A new design of trial for hypnotics comparison: A double-blind cross-over trial with patient's preference assessment and continuation of the preferred treatment</title><author>Bourin, Michel ; Malinge, Myriam</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c386t-84952c58b0119cc32d77f6d8eeba74ae869608812593da19a57c14021d72363f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1996</creationdate><topic>Adult</topic><topic>Anti-Anxiety Agents - therapeutic use</topic><topic>Benzodiazepines</topic><topic>Benzodiazepinones - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>common insomnia</topic><topic>cross-over trial</topic><topic>Female</topic><topic>Humans</topic><topic>Hypnotics. Sedatives</topic><topic>loprazolam</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Neuropharmacology</topic><topic>patient's preference</topic><topic>Pharmacology. Drug treatments</topic><topic>Psychology. Psychoanalysis. Psychiatry</topic><topic>Psychopharmacology</topic><topic>Sleep Initiation and Maintenance Disorders - drug therapy</topic><topic>triazolam</topic><topic>Triazolam - therapeutic use</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Bourin, Michel</creatorcontrib><creatorcontrib>Malinge, Myriam</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Progress in neuro-psychopharmacology & biological psychiatry</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Bourin, Michel</au><au>Malinge, Myriam</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>A new design of trial for hypnotics comparison: A double-blind cross-over trial with patient's preference assessment and continuation of the preferred treatment</atitle><jtitle>Progress in neuro-psychopharmacology & biological psychiatry</jtitle><addtitle>Prog Neuropsychopharmacol Biol Psychiatry</addtitle><date>1996-04-01</date><risdate>1996</risdate><volume>20</volume><issue>3</issue><spage>373</spage><epage>385</epage><pages>373-385</pages><issn>0278-5846</issn><eissn>1878-4216</eissn><coden>PNPPD7</coden><abstract>1.
1. This study compared two hypnotics administrated at comparable therapeutic dosages: triazolam (0.25 mg) and loprazolam (1 mg), were administered using an original scheme (cross-over on the first 2 nights, and continuation of the preferred treatment or new randomization).
2.
2. Sixty-seven outpatients complaining of common insomnia participated in this study conducted by general practitioners.
3.
3. Both drugs provided improvement in sleep quality (decreased sleep latency, increased total duration of sleep, decreased number of night awakenings), and are equally well tolerated.
4.
4. For the first 2 nights, triazolam was evaluated to be more efficient than loprazolam (p < 0.001) and patients felt more rested the following day (p < 0.01) with the former drug. Moreover, triazolam is more frequently preferred than loprazolam by 47.7% and 29.2%, respectively, (p = 0.09).
5.
5. No interaction was found between treatment and order of administration or specific effects and order of administration.</abstract><cop>Amsterdam</cop><pub>Elsevier Inc</pub><pmid>8771595</pmid><doi>10.1016/0278-5846(96)00003-6</doi><tpages>13</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0278-5846 |
| ispartof | Progress in neuro-psychopharmacology & biological psychiatry, 1996-04, Vol.20 (3), p.373-385 |
| issn | 0278-5846 1878-4216 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_78275509 |
| source | MEDLINE; Access via ScienceDirect (Elsevier) |
| subjects | Adult Anti-Anxiety Agents - therapeutic use Benzodiazepines Benzodiazepinones - therapeutic use Biological and medical sciences common insomnia cross-over trial Female Humans Hypnotics. Sedatives loprazolam Male Medical sciences Middle Aged Neuropharmacology patient's preference Pharmacology. Drug treatments Psychology. Psychoanalysis. Psychiatry Psychopharmacology Sleep Initiation and Maintenance Disorders - drug therapy triazolam Triazolam - therapeutic use |
| title | A new design of trial for hypnotics comparison: A double-blind cross-over trial with patient's preference assessment and continuation of the preferred treatment |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-17T01%3A36%3A45IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A%20new%20design%20of%20trial%20for%20hypnotics%20comparison:%20A%20double-blind%20cross-over%20trial%20with%20patient's%20preference%20assessment%20and%20continuation%20of%20the%20preferred%20treatment&rft.jtitle=Progress%20in%20neuro-psychopharmacology%20&%20biological%20psychiatry&rft.au=Bourin,%20Michel&rft.date=1996-04-01&rft.volume=20&rft.issue=3&rft.spage=373&rft.epage=385&rft.pages=373-385&rft.issn=0278-5846&rft.eissn=1878-4216&rft.coden=PNPPD7&rft_id=info:doi/10.1016/0278-5846(96)00003-6&rft_dat=%3Cproquest_cross%3E78275509%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=78275509&rft_id=info:pmid/8771595&rft_els_id=0278584696000036&rfr_iscdi=true |